Browsing Research Articles (School of Pharmacy) by Subject "Tuberculosis"
Now showing items 1-7 of 7
-
Acute pharmacokinetics of first line anti-tuberculosis drugs in patients with Pulmonary Tuberculosis and in patients with Pulmonary Tuberculosis co-infected with HIV
(David Publishing, 2011)The aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with pulmonary tuberculosis (PTB) and in patients with PTB and HIV during the first 24 h of treatment. Designed as a ... -
Amount of cycloserine emanating from terizidone metabolism and relationship with hepatic function in patients with drug resistant tuberculosis
(Springer, 2019)The dosing of cycloserine and terizidone is the same, as both drugs are considered equivalent or used interchangeably. Nevertheless, it is not certain from the literature that these drugs are interchangeable. Therefore, the ... -
Determination of kanamycin plasma levels using LC-MS and its pharmacokinetics in patients with multidrug-resistant tuberculosis with and without HIV-infection
(OMICS, 2015)The objectives of the study were: (1) to determine kanamycin plasma concentrations using liquid chromatography coupled with mass spectrometry (LC-MS), (2) to investigate kanamycin pharmacokinetics (PK) in patients with ... -
Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles
(Elsevier, 2022)Tuberculosis (TB) remains one of the deadliest communicable dis- eases caused by Mycobacterium tuberculosis (Mtb) since its discovery in the 1880s (Cambau and Drancourt, 2014; Singh et al., 2020). Over 1 billion mortalities ... -
Nanomedicines for infectious diseases
(Springer Nature, 2019)Infectious diseases continue to pose a significant threat to global health. Over 200 infectious diseases are currently known to man. Fortunately, only a handful are responsible for significant morbidity and mortality. ... -
Steady‐state population pharmacokinetics of terizidone and itsmetabolite cycloserine in patients with drug‐resistanttuberculosis
(Wiley, 2019)Despite terizidone being part of the second‐line recommended drugs fortreatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokineticsis scarce. The aim of this study was to describe the steady‐state ... -
Time trends in Tuberculosis mortality across the BRICS: An age-period-cohort analysis for the GBD 2019
(Elsevier, 2022)There were 549,522 tuberculosis deaths across the BRICS in 2019, accounting for 39.3% of global deaths. Among HIV-negative populations, the age-standardised mortality rate (ASMR) of tuberculosis in BRICS remained far ...